The FDA has approved atezolizumab (Tecentriq®) for use as an adjuvant treatment following resection and platinum-based chemotherapy in patients with stage II to IIIA non–small cell lung cancer whose tumors have PD-L1 expression on  1% or more  of tumor cells.

The decision was supported by data from the phase 3 IMpower010 trial. The FDA also approved the VENTANA PD-L1 (SP263) Assay as a companion diagnostic device to select patients with NSCLC for adjuvant treatment with atezolizumab. 

Read more